Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | KLK1 | P06870 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355205 | 0.89 | SMN1; SMN2 (0.40) | MEN1KMT2ATSHRTDP1 | |
| SCHEMBL353822 | 0.83 | BCL2 (0.40) | MEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL354841 | 0.81 | TAS1R3 (0.37) | MEN1KMT2ATSHRMAPK1L3MBTL1 | |
| SCHEMBL355339 | 0.80 | OXTR (0.37) | LPAR1TDP1TP53 | |
| SCHEMBL353665 | 0.78 | BCL2 (0.37) | MEN1KMT2AMAPK1ALDH1A1TDP1 | |
| SCHEMBL353452 | 0.75 | MEN1 (0.37) | MEN1KMT2ATSHRL3MBTL1TDP1 | |
| SCHEMBL3472763 | 0.74 | TAAR1 (0.58) | MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL353909 | 0.73 | MEN1 (0.43) | MEN1KMT2AL3MBTL1ALDH1A1TDP1 | |
| SCHEMBL353877 | 0.72 | BCL2L1 (0.64) | TDP1 | |
| SCHEMBL3474066 | 0.71 | KMT2A (0.52) | MEN1KMT2AALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418942-B1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | SANFORD-BURNHAM MEDICAL RES INST (US) | 2017-08-23 | — | — | EP | disclosed |
| US-8436207-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-01-19 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | HAX1, BAX, APOL1 | MEN1 4843/4885KMT2A 4765/4885TSHR 4468/4885 |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | HAX1, PRDX1, APOL1 | MEN1 4790/4885KMT2A 4720/4885TSHR 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.